Users Coming Off Weight-Loss Injections Regain Pounds Four Times Faster Compared to Those on Conventional Diets

Fresh analysis indicates that people who come off popular GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who end conventional lifestyle plans.

Findings released in a prominent medical journal demonstrates that while overweight people frequently drop about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.

"People purchasing these treatments must be aware of the risk of quick rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.

This pace of recovery implies a reversion to starting weight within about one and a half years.

Comparing Treatments

The study, which looked at dozens of studies involving over 9,000 of participants, compared the results of the injectable medications with conventional dieting.

Researchers point out that people who lose weight through diet and exercise usually experience a slower weight regain—perhaps 100 grams monthly—post-intervention.

Understanding the Rapid Regain

Experts believe the mechanism of the drugs is key to understanding the accelerated regain.

GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this hormone supplement means hunger is no longer kept in check, making excessive eating much more probable."

An Ongoing Disease?

The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.

Many experts say that, due to the high risk of relapse, the treatment should be considered life-long.

This perspective is supported by pharmaceutical companies, who state that the results "highlight the long-term character of excess weight," comparing it to managing conditions like high blood pressure.

Patient Accounts

Users who have stopped the medication explain a intense return of appetite.

"It felt as if something flipping and you become extremely hungry," said a patient.

The struggle is worsened if patients have not established sustainable dietary or behavioural changes during treatment.

Widespread Adoption

Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.

• Adoption is more common among women compared to men.
• The 40s and 50s age group shows the highest usage rates.
• Many access the drugs through private healthcare rather than the NHS.

Finally, researchers caution that while the jabs are effective agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on ongoing behavioural support.